Clear Cell Carcinoma Arising in an Abdominal Wall Cesarean Section Scar: A Case Report With Description of Pathological and Molecular Features

Cristina Colarossi, Maria Carolina Picardo, Lorenzo Colarossi, Enrica Deiana, Costanza D'Agata, Corrado Fichera, Eleonora Aiello, Giorgio Giannone and Lorenzo Memeo

Clear cell carcinoma is a clinically and biologically distinct type of carcinoma predominantly encountered in the ovary and endometrium. Its localization within an abdominal wall scar is extremely rare, and its pathogenesis is usually related to malignant transformation of endometriosis, which develops after hysterectomy or cesarean-section (c-section) (1, 2). We report a case involving a woman who developed CCC of the abdominal wall 16 years after c-section, and describe the histological, immunohistochemical, and molecular features. Although the diagnostic criteria are well-defined, this diagnosis can be challenging and requires extensive sampling of the lesion, especially when cystic and benign-appearing glands are predominant.

INTRODUCTION

Clear cell carcinoma (CCC) of the female genital tract is usually localized to the ovary or endometrium. Its localization within an abdominal wall scar is extremely rare, and its pathogenesis is usually related to malignant transformation of endometriosis, which develops after hysterectomy or cesarean-section (c-section) (1, 2). We report a case involving a woman who developed CCC of the abdominal wall 16 years after c-section, and describe the histological, immunohistochemical, and molecular features. Although the diagnostic criteria are well-defined, this diagnosis can be challenging and requires extensive sampling of the lesion, especially when cystic and benign-appearing glands are predominant.

CASE STUDY

In October 2018, a 52-year-old woman was admitted to the authors’ institute for a subcutaneous mass that developed on her c-section scar. The patient had no history of endometriosis, cancer,
revealed a solid mass, measuring 66 × 63 × 36 mm, with thin septa, is apparent in the rectus muscle of the abdomen in the suprapubic area (arrow).

or other relevant medical condition. Blood tests at admission were normal and tumor markers (CEA, CACA19.9) were negative. The patient underwent two cesarean deliveries via Pfannenstiel incision in 1999 and 2001, respectively. Physical examination revealed a subcutaneous smooth mass on the site of the c-section median scar. She had a non-painful, treatable abdomen. Ultrasound evaluation of the inferior abdomen showed a polytetrafluoroethylene prosthesis was placed. Subcutaneous resection surgical margins. The abdominal wall was repaired en-bloc with parietal peritoneum and skin, with disease-free resection surgical margins. The abdominal wall was repaired through suture of the anterior and posterior aponeurosis and a polytetrafluoroethylene prosthesis was placed. Subcutaneous drainage was removed on post-operative day 5 and the patient was discharged on day 6 after surgery with diagnosis of clear cell adenocarcinoma arising on a c-section scar. TC and PET 18-FDG negativity supported the diagnosis of primary carcinoma rather than metastasis. After 30 months of follow-up, the patient was in good condition and TC and PET 18-FDG were negative for disease relapse or metastasis, with negative serological tumor markers. The patient reported only some minor postoperative complications of abdominal wall repair. The patient perspective was taken in account when hysterectomy and bilateral salpingo-oophorectomy was considered.

Gross examination of the surgical sample revealed a well-defined nodular mass with cystic features. Histological analysis revealed carcinoma with papillary and tubulo-cystic architecture. The cells exhibited clear and eosinophilic cytoplasm and hyperchromatic nuclei with mild to moderate atypia (Figure 2A). Moreover, intermixed with atypical papillae, dilated cysts lined by flattened cells with benign-appearing nuclei were observed (Figure 2B). Mitotic figures were scant. Occasional small groups of clear cells were observed (Figure 2C). No foci of benign endometrial glands were found; however, dense fibrous tissue and hemorrhagic areas were present mainly in the peripheral area of the lesion (Figure 2D). Immunohistochemical analysis revealed expression of CK7, PAX8, napsin-A, ARID1A, and membranous beta-catenin (Figure 3) in neoplastic cells, and negativity for ER, PR, CA125, CDX2, TTF1 and calretinin. Immunohistochemistry for p53 showed an heterogeneous expression in 20% of tumor cells so was considered TP53 wild type. Microsatellites were stable, with nuclear expression of MLH1, MSH2, MSH6, and PMS2. Real-time polymerase chain reaction (PCR) revealed the presence of the E545 mutation in PIK3CA in the helical domain of exon 9.

**DISCUSSION**

CCC is usually localized to the ovaries and endometrium. In the ovary, CCC represents 3–10% of epithelial carcinomas, depending on geographical location and ethnicity. Compared to serous carcinoma of the ovary, it usually appears at a younger age (55 vs. 64 years of age) and at a lower stage, which is usually associated with a better prognosis (1). In the abdominal wall, it is very rare, with approximately 30 cases described to date (2). As commonly reported for ovarian CCC, endometriosis is considered to be precursor lesion of CCC in the abdominal wall (3). The surgical scar from c-section is the most common site for extrapelvic endometriosis, with an incidence between 0.07 and 0.4%. In contrast, malignant transformation is a very rare event, accounting for < 1% of cases (4), and CCC is the most frequent neoplastic lesion associated with endometriosis in the abdominal wall (5). Diagnosis of this malignancy requires the demonstration of both benign and neoplastic endometrial tissues in the tumor (6). In our case, endometriosis consisted primarily of stromal cells, without evidence of normal endometrial glands in the extensive sampling examined. Recently, beyond histological features, the molecular mechanisms underlying malignant transformation have been investigated. Anglesio et al. (7) described the presence of somatic mutations in deep infiltrating endometriosis without cancer, including mutations in PIK3CA, KRAS, and ARID1A. Loss of BAF250a (ARID1A gene) is also frequent in atypical endometriosis, suggesting its early contribution to carcinogenesis (8), and mutations in PIK3CA and ARID1A are common in CCC of the ovary (9), with PIK3CA being mutated in up to 35% of CCCs and ARID1A in 40%, which is associated with poor prognosis in stage I and II ovarian carcinomas. We detected E545 PIK3CA mutation in exon 9 using real-time polymerase chain reaction, whereas the tumor exhibited preserved expression of the ARID1A protein according to immunohistochemical...
FIGURE 2 | Histological images of the tumor. Carcinoma with papillary and tubule-cystic architecture. The cells exhibit clear and eosinophilic cytoplasm and hyperchromatic nuclei with mild to moderate atypia (arrow) (A; H&E, 5x). Dilated cysts lined by flattened cells with benign-appearing nuclei intermixed with atypical papillae (arrow) (B; H&E, 10x). Occasional small groups of clear cells (arrow) (C; H&E, 10x). Irregular infiltrating glands with dense fibrous stroma (arrow) (D; H&E, 10x).

FIGURE 3 | Immunohistochemical profile: diffuse expression of ARID1A (A, 20x), CK7 (B, 20x); napsin-A (C, 20x), and PAX8 (D, 20x).

analysis. Loss of expression is correlated with inactivating mutations of ARID1A and poor prognosis in stage I/II ovarian CCC (10). Intact nuclear expression in our case appears to be consistent with the clinical history of the patient, who did not experience any recurrence or metastasis. As expected, β-catenin exhibited membranous expression on immunohistochemistry. Nuclear and aberrant expression, which is typical of ovarian endometrioid carcinoma, is highly correlated with CTNNBI mutation (11), but it has never been described in CCC (12). Despite the accumulation of molecular information, we did not find a consensus regarding specific treatment strategies. Radical surgery of a mass with disease-free margins is considered to be the best option. In some described cases, a bilateral aneisectomy was performed (13); however, in our patient, surgical exploration, PET, and CT did not reveal any suspicious lesions at other sites. A multicenter study reported that adjuvant chemotherapy was not effective in stage I ovarian CCC (14). Several studies have considered experimental target therapies. PI3K pathway inhibitors may be considered for tumors with PIK3CA mutations (15). In our case, chemotherapy was not recommended by our oncologists or in other referral centers where the patient visited for a second opinion. Twenty-nine months after surgery, the patient is in a good health with no evidence of recurrence.
The increasing rate of c-sections requires more awareness of the existence of endometriosis in the scar site and the possibility—although highly limited—of malignant transformation. All reported cases suggest that a previous surgical procedure involving opening of the endometrial cavity may be a predisposing factor for the development of endometriosis implants in the abdominal wall. C-section is the most frequent surgical procedure associated with abdominal wall endometriosis, and also appears to be the most frequent surgery reported in cases of cancer derived from abdominal endometriosis implants.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

REFERENCES

1. Fujiwara K, Shintani D, Nishikawa T. Clear-cell carcinoma of the ovary. Ann Oncol. (2016) 27(Suppl. 1):S50–2. doi: 10.1093/annonc/mdv086
2. Giannella L, Serri M, Maccaroni E, Di Giuseppe J, Delli Carpini G, Berardi R, et al. Endometriosis-associated clear cell carcinoma of the abdominal wall after caesarean section: a case report and review of the literature. In vivo. (2020) 34:2147–52. doi: 10.21873/invivo.12021
3. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extratubal malignancies. Int J Gynecol Pathol. (2001) 20:133–9. doi: 10.1097/00004347-200104000-00004
4. Taburiaux L, Pluchino N, Petignat P. Endometriosis-associated abdominal wall cancer: a poor prognosis? Int J Gynecol Cancer. (2015) 25:1633–8. doi: 10.1097/IGC.0000000000000556
5. Ferrandina G, Palluzzi E, Fanfani F; Gentleschi S, Valentinii AL, Mattoli MV, et al. Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature. World J Surg Oncol. (2016) 14:300. doi: 10.1186/s12957-016-1054-7
6. Sampson J. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg. (1925) 10:1–72. doi: 10.1001/archsurg.1925.012010007001
7. Anglesio MS, Papadopoulous N, Ayhan A, Nazeran TM, Noe M, Horlings HM, et al. Cancer-associate mutations in endometriosis without cancer. N Engl J Med. (2017) 376:1835–48. doi: 10.1056/NEJMoai1614814
8. Stamp JP, Gilks CB, Wesseling M, Eshragh S, Ceballos K, Anglesio MS, et al. BAF250A expression in atypical endometriosis and endometriosis-associated ovarian cancer. Int J Gynecol Cancer. (2016) 26:823–32. doi: 10.1097/IGC.0000000000000698
9. Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. (2021) 31:605–16. doi: 10.1111/ijgc.2020-001659
10. Itamochi H, Oumi N, Oishi T, Shoji T, Fujiwara H, Sugiyama T, et al. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. Int J Clin Oncol. (2015) 20:967–73. doi: 10.1007/s10147-015-0811-x
11. Zyla R, Olikhov-Mitsel E, Amemiya Y. CTNNB1 mutations and aberrant β-catenin expression in ovarian endometrioid carcinoma: correlation with patient outcome. Am J Surg Pathol. (2021) 45:68–76. doi: 10.1097/PAS.0000000000001553
12. Matsumoto T, Yamazaki M, Takahashi H, Kajita S, Suzuki E, Tsuruta T, Saegusa M. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Am J Clin Pathol. (2015) 144:452–63. doi: 10.1093/ajcp/zst006
13. Marques C, Silva TS, Dias MF. Clear cell carcinoma arising from abdominal wall endometriosis: brief report and review of the literature. Gynecol Oncol Rep. (2017) 20:78–80. doi: 10.1016/j.gore.2017.03.008
14. Takano M, Sugiyama T, Yaegashi Y. Less impact of stage I clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study. Int J Gynecol Cancer. (2010) 20:1506–10. doi: 10.1111/J.1525-157X.2010.01191.X
15. Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecol Oncol. (2018) 151:381–9. doi: 10.1016/j.ygyno.2018.09.001

ETHICS STATEMENT

Written informed consent was obtained from the individual for publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

MP, LC, ED, CD’A, CF, EA, and GG drafted the manuscript. CC and LM edited the manuscript. All authors were involved in the clinical care of the patient and approved the final version of the manuscript at the time of submission.

ACKNOWLEDGMENTS

The authors thank Maria Rita Pulviento, Giovanni Ferlito, and Simone Viola for their technical assistance and Editage (www.editage.com) for English language editing.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Colarossi, Picardo, Colarossi, Deiana, D’Agata, Fichera, Aiello, Giannone and Memeo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.